Brokerages Set Perspective Therapeutics, Inc. (NYSE:CATX) Target Price at $15.14

Perspective Therapeutics, Inc. (NYSE:CATX) has earned an average rating of “Moderate Buy” from the nine brokerages that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $15.14.

Several brokerages recently issued reports on CATX. UBS Group initiated coverage on Perspective Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $20.00 price target for the company. Oppenheimer decreased their target price on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, November 22nd. Bank of America lowered shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $24.00 to $5.00 in a research report on Monday, November 25th. Royal Bank of Canada restated an “outperform” rating and set a $16.00 price objective on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $11.00 target price on shares of Perspective Therapeutics in a report on Friday.

Insider Transactions at Perspective Therapeutics

In other Perspective Therapeutics news, Director Heidi Henson bought 25,975 shares of the firm’s stock in a transaction dated Wednesday, December 4th. The shares were purchased at an average price of $3.85 per share, for a total transaction of $100,003.75. Following the transaction, the director now directly owns 25,975 shares of the company’s stock, valued at approximately $100,003.75. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Johan M. Spoor bought 14,500 shares of the firm’s stock in a transaction dated Monday, November 25th. The stock was purchased at an average price of $3.78 per share, for a total transaction of $54,810.00. Following the transaction, the chief executive officer now owns 152,072 shares of the company’s stock, valued at approximately $574,832.16. This represents a 10.54 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 67,570 shares of company stock worth $256,789 over the last three months. 3.52% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Perspective Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Rhumbline Advisers acquired a new stake in Perspective Therapeutics during the second quarter worth $630,000. Victory Capital Management Inc. acquired a new position in shares of Perspective Therapeutics in the second quarter valued at approximately $117,000. Renaissance Technologies LLC increased its stake in Perspective Therapeutics by 94.2% during the 2nd quarter. Renaissance Technologies LLC now owns 61,660 shares of the company’s stock worth $615,000 after buying an additional 29,914 shares during the period. HighVista Strategies LLC acquired a new stake in Perspective Therapeutics during the 2nd quarter worth approximately $1,132,000. Finally, Ally Bridge Group NY LLC acquired a new stake in Perspective Therapeutics during the 2nd quarter worth approximately $3,951,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

Perspective Therapeutics Price Performance

NYSE:CATX opened at $4.01 on Friday. Perspective Therapeutics has a fifty-two week low of $2.70 and a fifty-two week high of $19.05. The business has a 50 day moving average price of $3.68 and a 200-day moving average price of $9.75.

Perspective Therapeutics (NYSE:CATX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, hitting the consensus estimate of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The firm had revenue of $0.37 million during the quarter. As a group, research analysts forecast that Perspective Therapeutics will post -0.88 earnings per share for the current year.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.